Periodontal Therapeutic Market Research Report – Forecast to 2030

Periodontal Therapeutic Market Research Report: By Type (Chronic Periodontitis Aggressive Periodontitis and Necrotizing Periodontal), by Treatment (Systematic Antibiotics and Others), by End-Users (Dental Hospital and Others)-Forecast Till 2030

ID: MRFR/Pharma/5100-HCR | December 2022 | Region: Global | 100 Pages         

Periodontal Therapeutic Market

Periodontal Therapeutic Market Is Projected To Reach $536.8 Million, Enlisting a CAGR Of 10.3% By 2030

Segmentation

By Type Chronic Periodontitis Aggressive Periodontitis Necrotizing Periodontal)
by Treatment Systematic Antibiotics Others
by End-Users Dental Hospital Others

Key Players

  • Fibrocell Sciences
  • Tolmar Inc
  • Eli Lilly & Company
  • Align Technology
  • Dentsply International
  • 3M-ESPE
  • Ultradent Products Inc
  • Nobel Biocare Holdings AG
  • Glidewell Laboratories
  • Orapharma
  • Kaken Pharmaceutical
  • Valeant Pharmaceuticals Int.

Drivers

  • Smoking
  • poor oral hygiene
  • hormonal changes in females
  • diabetes mellitus
Speak to Analyst Request a Free Sample

Periodontal Therapeutics Market Overview


Periodontal therapy market is expected to reach USD 1.5 billion by 2030 at 9.2% CAGR during the forecast period 2022-2030. Periodontal disease is a chronic inflammatory illness that affects the gums and the bone that supports the teeth. It can result in tooth loss and other major health issues if left untreated. Periodontal disease must be treated early to avoid chronic inflammation, which can contribute to insulin resistance, impaired glucose tolerance, and an increased risk of diabetes. The sooner it's dealt with, the better. However, today's oral health programs help to manage diet and nutrition risk factors for dental disorders such as periodontal disease.


As the world's population ages, periodontal diseases are growing more widespread, boosting the global market for periodontal therapy. Because of the increased prevalence of periodontal illnesses among the senior population, the North American market is expected to dominate the worldwide periodontal therapeutics market. With increasing rates of an elderly population suffering from diabetes, a sedentary lifestyle, and an efficient reimbursement scenario, Europe is expected to drive the growth of the periodontal therapy market over time.


Periodontal Therapeutics Market Segmentation


The global periodontal therapeutic market has been segmented on basis of type, treatment, and end-users. On basis of type, the market is segmented into three types such as gingivitis, chronic periodontitis, aggressive periodontitis, and necrotizing periodontal disease. Based on treatment, the market is segmented into two segments such as systematic antibiotics and local antibiotics. Systematic antibiotics are further sub-segmented into doxycycline, minocycline, metronidazole, and others. Local antibiotics are further segmented into arestin, chlorhexidine, and others. On basis of end-user market is further is segmented into dental clinics and hospitals. 


Periodontal Therapeutics Market Key players



  • Fibrocell Sciences, Inc

  • Tolmar Inc

  • Eli Lilly & Company

  • Align Technology Inc

  • Dentsply International

  • 3M-ESPE

  • Ultradent Products Inc

  • Nobel Biocare Holdings AG

  • Glidewell Laboratories, Inc

  • Orapharma

  • Kaken Pharmaceutical

  • Valeant Pharmaceuticals Int. Inc

  • Den-Mat Holdings

  • Mallinckrodt Pharmaceuticals

  • Purdue Pharma L.P.

  • Teva Pharmaceutical Industries Limited.


Periodontal Therapeutics Market Regional Market Summary


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The periodontal therapeutic market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European periodontal therapeutic global market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The periodontal therapeutic market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The periodontal therapeutic market in the Middle East and Africa has been segmented into the Middle East and Africa.


On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Middle East and Africa. The North American market is anticipated to dominate the periodontal therapeutic global market due to rising prevalence of periodontal diseases among the geriatric population.  According to recent findings from the Centre for Disease Control and Prevention (CDC), half of Americans aged 30 or older have periodontitis, the more advanced form of periodontal disease. This equals approximately 64.7 million Americans are suffering from periodontal diseases.  


Europe is anticipated to drive the growth of the periodontal therapeutic market in upcoming years due to increasing incidences of an aging population suffering from diabetes, sedentary lifestyle and efficient reimbursement scenario.


Asia-Pacific is projected to register robust growth in the future due to large patient population and growing healthcare infrastructure and expenditure.


The Middle East and Africa is expected to account for the lowest market share in the global periodontal therapeutic market due to the lack of advanced technology and poor medical facilities in developing economies in this region.

Periodontal Therapeutics Market Recent Development


VideaHealth's cavity-spotting AI received FDA approval recently. The AI was created and taught with VideaHealth's large library of dental X-rays, the Videa Factory, which the business claims are the most diversified data set in the dental sector. It includes more than 100 million data points from dental service providers, insurance companies, clearinghouses, and institutions. The AI is said to have helped dentists overlook 43 percent fewer caries lesions. It also reduced their inaccurate diagnoses by 15%.


The European Commission recently approved CABOMETYX (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are refractory or ineligible to radioactive iodine (RAI) and who have progressed during or after prior systemic therapy. This approval authorizes CABOMETYX to be marketed under this indication in all 27 European Union member states, as well as Norway, Liechtenstein, and Iceland.


Periodontal Therapeutics Market, by Types



  • Gingivitis

  • Chronic periodontitis

  • Aggressive periodontitis

  • Necrotizing periodontal disease


Periodontal Therapeutics Market, by Treatment



  • Systematic Antibiotics

  • Doxycycline

  • Minocycline

  • Metronidazole

  • Others

  • Local Antibiotics

  • Arestin

  • Chlorhexidine

  • Others


Periodontal Therapeutics Market, by End-Users



  • Dental clinics

  • Hospital


Periodontal Therapeutic Global Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • South America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Middle East & Africa

    • Middle East

    • Africa




 Intended Audience



  • Dental equipment manufacturers

  • Vendors and distributors of dental systems

  • Research and Development (R&D) companies

  • Raw material suppliers

  • General dentists and cosmetic dentists

  • Government Research Institutes

  • Academic institutes and universities



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 1.5 Billion
  CAGR   9.2%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Basis Of Type, Treatment, and End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Fibrocell Sciences, Inc, Tolmar Inc, Eli Lilly & Company, Align Technology Inc., Dentsply International, 3M-ESPE, Ultradent Products Inc, Nobel Biocare Holdings AG, Glidewell Laboratories, Inc, Orapharma, Kaken Pharmaceutical, Valeant Pharmaceuticals Int. Inc, Den-Mat Holdings, Mallinckrodt Pharmaceuticals, Purdue Pharma L.P., Teva Pharmaceutical Industries Limited.
  Key Market Opportunities   Increasing aging population has increased incidences of periodontal diseases
  Key Market Drivers   Smoking, poor oral hygiene, hormonal changes in females, diabetes mellitus, stress are responsible for periodontal diseases


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Periodontal Therapeutic Market is projected to grow at a 9.2% CAGR between 2022-2030.

North America is projected to command the largest share in Periodontal Therapeutic Market.

End use industries of Periodontal Therapeutic Market include hospitals and dental clinics.

Rising incidences of periodontal diseases is boosting market growth.

Casual approach towards oral hygiene may limit market growth.